Part III - Case Studies
Published online by Cambridge University Press: 13 March 2025
- Type
- Chapter
- Information
- Rethinking Clinical ResearchMethodology and Ethics, pp. 251 - 355Publisher: Cambridge University PressPrint publication year: 2025
References
References
Zhang, D, Liu, S, Li, Z, Wang, R. Global, regional and national burden of gastroesophageal reflux disease, 1990–2019: Update from the GBD 2019 study. Ann Med. 2022; 54(1):1372–1384. doi:10.1080/07853890.2022.2074535.CrossRefGoogle ScholarPubMed
El-Serag, HB, Sweet, S, Winchester, CC, Dent, J. Update on the epidemiology of gastro-oesophageal reflux disease: A systematic review. Gut. 2014; 63(6):871–880. doi:10.1136/gutjnl-2012-304269.CrossRefGoogle ScholarPubMed
Centers for Disease Control and Prevention. Health, United States, 2016 – Individual Charts and Tables: Spreadsheet, PDF, and PowerPoint files. Table 80. Selected prescription drug classes used in the past 30 days, by sex and age: United States, selected years 1988–1994 through 2011–2014. 2016. www.cdc.gov/nchs/data/hus/2016/080.pdf.Google Scholar
Targownik, LE, Fisher, DA, Saini, SD. AGA clinical practice update on de-prescribing of proton pump inhibitors: Expert review. Gastroenterology. 2022; 162(4):1334–1342. doi:10.1053/j.gastro.2021.12.247.CrossRefGoogle ScholarPubMed
Barberio, B, Visaggi, P, Savarino, E, de Bortoli, N, Black, CJ, Ford, AC. Comparison of acid-lowering drugs for endoscopy negative reflux disease: Systematic review and network meta-analysis. Neurogastroenterol Motil. 2023; 35(1):e14469. doi:10.1111/nmo.14469.CrossRefGoogle ScholarPubMed
Elliott, N, Steel, A, Leech, B, Peng, W. Design characteristics of comparative effectiveness trials for the relief of symptomatic dyspepsia: A systematic review. Integr Med Res. 2021; 10(2):100663. doi:10.1016/j.imr.2020.100663.CrossRefGoogle ScholarPubMed
Chiu, CT, Hsu, CM, Wang, CC, et al. Randomised clinical trial: Sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease. Aliment Pharmacol Ther. 2013; 38(9):1054–1064. doi:10.1111/apt.12482.CrossRefGoogle ScholarPubMed
Manabe, N, Haruma, K, Ito, M, et al. Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: A randomized clinical trial. Dis Esophagus. 2012; 25(5):373–380. doi:10.1111/j.1442-2050.2011.01276.x.CrossRefGoogle ScholarPubMed
Hosseini, M, Salari, R, Akbari Rad, M, Salehi, M, Birjandi, B, Salari, M. Comparing the effect of psyllium seed on gastroesophageal reflux disease with oral omeprazole in patients with functional constipation. J Evid Based Integr Med. 2018; 23:2515690X18763294. doi:10.1177/2515690X18763294.CrossRefGoogle ScholarPubMed
Armstrong, D, Talley, NJ, Lauritsen, K, et al. The role of acid suppression in patients with endoscopy-negative reflux disease: The effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther. 2004; 20(4):413–421. doi:10.1111/j.1365-2036.2004.02085.x.CrossRefGoogle ScholarPubMed
Bate, CM, Griffin, SM, Keeling, PW, et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther. 1996; 10(4):547–555. doi:10.1046/j.1365-2036.1996.44186000.x.CrossRefGoogle ScholarPubMed
Bate, CM, Green, JR, Axon, AT, et al. Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. Aliment Pharmacol Ther. 1997; 11(4):755–763. doi:10.1046/j.1365-2036.1997.00198.x.CrossRefGoogle ScholarPubMed
Carlsson, R, Dent, J, Watts, R, et al. Gastro-oesophageal reflux disease in primary care: An international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol. 1998; 10(2):119–124.CrossRefGoogle Scholar
Fujiwara, Y, Higuchi, K, Nebiki, H, et al. Famotidine vs. omeprazole: A prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2005; 21(Suppl 2):10–18. doi:10.1111/j.1365-2036.2005.02468.x.CrossRefGoogle ScholarPubMed
Lind, T, Havelund, T, Carlsson, R, et al. Heartburn without oesophagitis: Efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol. 1997; 32(10):974–979. doi:10.3109/00365529709011212.CrossRefGoogle ScholarPubMed
Richter, JE, Peura, D, Benjamin, SB, Joelsson, B, Whipple, J. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med. 2000; 160(12):1810–1816. doi:10.1001/archinte.160.12.1810.CrossRefGoogle ScholarPubMed
Uemura, N, Inokuchi, H, Serizawa, H, et al. Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux disease. J Gastroenterol. 2008; 43(9):670–678. doi:10.1007/s00535-008-2214-5.CrossRefGoogle ScholarPubMed
Venables, TL, Newland, RD, Patel, AC, Hole, J, Wilcock, C, Turbitt, ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol. 1997; 32(10):965–973. doi:10.3109/00365529709011211.CrossRefGoogle ScholarPubMed
Cohen, J. A power primer. Psychol Bull. 1992; 112(1):155–159. doi:10.1037//0033-2909.112.1.155.CrossRefGoogle ScholarPubMed
Drug Discovery Online. Patent expiry looms: 18 blockbusters expose $37 billion to generic competition by 2005. 2000.Google Scholar
Food and Drug Administration. Drug Approval Package: Nexium (Esomeprazole Magnesium) Delayed-Release Capsules. 2001.Google Scholar
Abramson, J. Sickening: How Big Pharma Broke American Health Care and How We Can Repair It. Mariner Books; 2022.Google Scholar
Fass, R, Boeckxstaens, GE, El-Serag, H, Rosen, R, Sifrim, D, Vaezi, MF. Gastro-oesophageal reflux disease. Nat Rev Dis Primers. 2021; 7(1):55. doi:10.1038/s41572-021-00287-w.CrossRefGoogle ScholarPubMed
Ness-Jensen, E, Lindam, A, Lagergren, J, Hveem, K. Weight loss and reduction in gastroesophageal reflux. A prospective population-based cohort study: The HUNT study. Am J Gastroenterol. 2013; 108(3):376–382. doi:10.1038/ajg.2012.466.CrossRefGoogle ScholarPubMed
Ness-Jensen, E, Lindam, A, Lagergren, J, Hveem, K. Tobacco smoking cessation and improved gastroesophageal reflux: A prospective population-based cohort study: The HUNT study. Am J Gastroenterol. 2014; 109(2):171–177. doi:10.1038/ajg.2013.414.CrossRefGoogle ScholarPubMed
Ness-Jensen, E, Hveem, K, El-Serag, H, Lagergren, J. Lifestyle intervention in gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2016; 14(2):175–182.e1–e3. doi:10.1016/j.cgh.2015.04.176.CrossRefGoogle ScholarPubMed
Ness-Jensen, E, Lagergren, J. Tobacco smoking, alcohol consumption and gastro-oesophageal reflux disease. Best Pract Res Clin Gastroenterol. 2017; 31(5):501–508. doi:10.1016/j.bpg.2017.09.004.CrossRefGoogle ScholarPubMed
Eusebi, LH, Ratnakumaran, R, Yuan, Y, Solaymani-Dodaran, M, Bazzoli, F, Ford, AC. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: A meta-analysis. Gut. 2018; 67(3):430–440. doi:10.1136/gutjnl-2016-313589.CrossRefGoogle ScholarPubMed
National Institute of Heart, Lung, and Blood. Calculate your body mass index. Accessed July 23, 2023. www.nhlbi.nih.gov/health/educational/lose_wt/BMI/bmi-m.htm.Google Scholar
Boeckxstaens, G, El-Serag, HB, Smout, AJ, Kahrilas, PJ. Symptomatic reflux disease: The present, the past and the future. Gut. 2014; 63(7):1185–1193. doi:10.1136/gutjnl-2013-306393.CrossRefGoogle ScholarPubMed
Lu, B, Zhang, L, Wang, J, et al. Empirical treatment of outpatients with gastroesophageal reflux disease with proton pump inhibitors: A survey of Chinese patients (the ENLIGHT Study). J Gastroenterol Hepatol. 2018; 33(10):1722–1727. doi:10.1111/jgh.14143.CrossRefGoogle Scholar
Jain, S, Shamrao Kulkarni, S, Mahapatra, JR, et al. Effectiveness of omeprazole in acid peptic disease: A real-world, patient-reported outcome measures study. Cureus. 2023; 15(7):e41994. doi:10.7759/cureus.41994.Google ScholarPubMed
Yadlapati, R, Gyawali, CP, Pandolfino, JE, Participants, CGCC. AGA clinical practice update on the personalized approach to the evaluation and management of GERD: Expert review. Clin Gastroenterol Hepatol. 2022; 20(5):984–994.e1. doi:10.1016/j.cgh.2022.01.025.CrossRefGoogle Scholar
Ware, JE, Snow, KK, Kosinski, M, Gandek, B. SF-36 Health Survey Manual and Interpretation Guide. The Health Institute, New England Medical Center; 1993.Google Scholar
Wiklund, IK, Junghard, O, Grace, E, et al. Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg Suppl. 1998; 583:41–49.Google Scholar
Talley, NJ, Wiklund, I. Patient reported outcomes in gastroesophageal reflux disease: An overview of available measures. Qual Life Res. 2005; 14(1):21–33. doi:10.1007/s11136-004-0613-5.CrossRefGoogle ScholarPubMed
Prasad, M, Rentz, AM, Revicki, DA. The impact of treatment for gastro-oesophageal reflux disease on health-related quality of life: A literature review. Pharmacoeconomics. 2003; 21(11):769–790. doi:10.2165/00019053-200321110-0002.CrossRefGoogle ScholarPubMed
Kamolz, T, Pointner, R, Velanovich, V. The impact of gastroesophageal reflux disease on quality of life. Surg Endosc. 2003; 17(8):1193–1199. doi:10.1007/s00464-002-9229-4.CrossRefGoogle ScholarPubMed
Velanovich, V. Quality of life and severity of symptoms in gastro-oesophageal reflux disease: A clinical review. Eur J Surg. 2000;166(7):516–525. doi:10.1080/110241500750008565.CrossRefGoogle ScholarPubMed
El-Dika, S, Guyatt, GH, Armstrong, D, et al. The impact of illness in patients with moderate to severe gastro-esophageal reflux disease. BMC Gastroenterol. 2005; 5:23. doi:10.1186/1471-230X-5-23.CrossRefGoogle ScholarPubMed
Wahlqvist, P. Symptoms of gastroesophageal reflux disease, perceived productivity, and health-related quality of life. Am J Gastroenterol. 2001; 96(8 Suppl):S57–S61. doi:10.1016/s0002-9270(01)02590-4.CrossRefGoogle ScholarPubMed
Mokrowiecka, A, Jurek, K, Pińkowski, D, Małecka-Panas, E. The comparison of Health-Related Quality of Life (HRQL) in patients with GERD, peptic ulcer disease and ulcerative colitis. Adv Med Sci. 2006; 51:142–147.Google ScholarPubMed
Revicki, DA, Wood, M, Maton, PN, Sorensen, S. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med. 1998; 104(3):252–258. doi:10.1016/s0002-9343(97)00354-9.CrossRefGoogle ScholarPubMed
Fallone, CA, Guyatt, GH, Armstrong, D, et al. Do physicians correctly assess patient symptom severity in gastro-oesophageal reflux disease? Aliment Pharmacol Ther. 2004; 20(10):1161–1169. doi:10.1111/j.1365-2036.2004.02257.x.CrossRefGoogle ScholarPubMed
Schünemann, HJ, Armstrong, D, Degl’innocenti, A, et al. A randomized multicenter trial to evaluate simple utility elicitation techniques in patients with gastroesophageal reflux disease. Med Care. 2004; 42(11):1132–1142. doi:10.1097/00005650-200411000-00013.CrossRefGoogle ScholarPubMed
Kaplan-Machlis, B, Spiegler, GE, Zodet, MW, Revicki, DA. Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia. Arch Fam Med. 2000; 9(7):624–630. doi:10.1001/archfami.9.7.624.CrossRefGoogle ScholarPubMed
Aimi, M, Komazawa, Y, Hamamoto, N, et al. Effects of omeprazole on sleep disturbance: Randomized multicenter double-blind placebo-controlled trial. Clin Transl Gastroenterol. 2014; 5(6):e57. doi:10.1038/ctg.2014.8.CrossRefGoogle ScholarPubMed
Chan, Y, Ching, JY, Cheung, CM, et al. Development and validation of a disease-specific quality of life questionnaire for gastro-oesophageal reflux disease: The GERD-QOL questionnaire. Aliment Pharmacol Ther. 2010; 31(3):452–460. doi:10.1111/j.1365-2036.2009.04187.x.CrossRefGoogle ScholarPubMed
Feeny, D, Furlong, W, Torrance, GW, et al. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care. 2002; 40(2):113–128.CrossRefGoogle ScholarPubMed
Kaplan, RM, Ganiats, TG, Sieber, WJ, Anderson, JP. The Quality of Well-Being Scale: Critical similarities and differences with SF-36. Int J Qual Health Care. 1998; 10(6):509–520.CrossRefGoogle ScholarPubMed
Furlong, WJ, Feeny, DH, Torrance, GW, Barr, RD. The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med. 2001; 33(5):375–384. doi:10.3109/07853890109002092.CrossRefGoogle ScholarPubMed
Kartman, B. Utility and willingness to pay measurements among patients with gastroesophageal reflux disease. Am J Gastroenterol. 2001; 96(8 Suppl):S38–S43. doi:10.1016/s0002-9270(01)02581-3.CrossRefGoogle ScholarPubMed
Heudebert, GR, Marks, R, Wilcox, CM, Centor, RM. Choice of long-term strategy for the management of patients with severe esophagitis: A cost-utility analysis. Gastroenterology. 1997; 112(4):1078–1086. doi:10.1016/s0016-5085(97)70118-5.CrossRefGoogle ScholarPubMed
Goeree, R, Hopkins, R, Marshall, JK, et al. Cost-utility of laparoscopic Nissen fundoplication versus proton pump inhibitors for chronic and controlled gastroesophageal reflux disease: A 3-year prospective randomized controlled trial and economic evaluation. Value Health. 2011; 14(2):263–273. doi:10.1016/j.jval.2010.09.004.CrossRefGoogle ScholarPubMed
Thijssen, AS, Broeders, IA, de Wit, GA, Draaisma, WA. Cost-effectiveness of proton pump inhibitors versus laparoscopic Nissen fundoplication for patients with gastroesophageal reflux disease: A systematic review of the literature. Surg Endosc. 2011; 25(10):3127–3134. doi:10.1007/s00464-011-1689-y.CrossRefGoogle ScholarPubMed
Office for Health Improvement and Disparities, National Institute for Health and Care Excellence. Cost utility analysis: Health economic studies. Accessed June 3, 2023, www.gov.uk/guidance/cost-utility-analysis-health-economic-studies.Google Scholar
Mafi, JN, May, FP, Kahn, KL, et al. Low-value proton pump inhibitor prescriptions among older adults at a large academic health system. J Am Geriatr Soc. 2019; 67(12):2600–2604. doi:10.1111/jgs.16117.CrossRefGoogle Scholar
Reimer, C, Søndergaard, B, Hilsted, L, Bytzer, P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009; 137(1):80–87, 87.e1. doi:10.1053/j.gastro.2009.03.058.CrossRefGoogle ScholarPubMed
Reimer, C, Bytzer, P. Clinical trial: Long-term use of proton pump inhibitors in primary care patients – A cross sectional analysis of 901 patients. Aliment Pharmacol Ther. 2009; 30(7):725–732. doi:10.1111/j.1365-2036.2009.04092.x.CrossRefGoogle ScholarPubMed
Wilhelm, SM, Rjater, RG, Kale-Pradhan, PB. Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Rev Clin Pharmacol. 2013; 6(4):443–451. doi:10.1586/17512433.2013.811206.CrossRefGoogle ScholarPubMed
Ngamruengphong, S, Leontiadis, GI, Radhi, S, Dentino, A, Nugent, K. Proton pump inhibitors and risk of fracture: A systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011; 106(7):1209–1218; quiz 1219. doi:10.1038/ajg.2011.113.CrossRefGoogle ScholarPubMed
Bavishi, C, Dupont, HL. Systematic review: The use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011; 34(11–12):1269–1281. doi:10.1111/j.1365-2036.2011.04874.x.CrossRefGoogle ScholarPubMed
Huber, MA, Nadella, S, Cao, H, et al. Does chronic use of high dose proton pump inhibitors increase risk for pancreatic cancer? Pancreas. 2022; 51(9):1118–1127. doi:10.1097/MPA.0000000000002145.CrossRefGoogle ScholarPubMed
Guo, H, Zhang, R, Zhang, P, et al. Association of proton pump inhibitors with gastric and colorectal cancer risk: A systematic review and meta-analysis. Front Pharmacol. 2023; 14:1129948. doi:10.3389/fphar.2023.1129948.CrossRefGoogle Scholar
Onwuzo, S, Boustany, A, Khaled Abou Zeid, H, et al. Prevalence and risk factors associated with inflammatory bowel disease in patients using proton-pump inhibitors: A population-based study. Cureus. 2023; 15(1):e34088. doi:10.7759/cureus.34088.Google ScholarPubMed
Jacobson, BC, Somers, SC, Fuchs, CS, Kelly, CP, Camargo, CA. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med. 2006; 354(22):2340–2348. doi:10.1056/NEJMoa054391.CrossRefGoogle ScholarPubMed
de Bortoli, N, Guidi, G, Martinucci, I, et al. Voluntary and controlled weight loss can reduce symptoms and proton pump inhibitor use and dosage in patients with gastroesophageal reflux disease: A comparative study. Dis Esophagus. 2016; 29(2):197–204. doi:10.1111/dote.12319.CrossRefGoogle ScholarPubMed
Yadlapati, R, Pandolfino, JE, Alexeeva, O, et al. The Reflux Improvement and Monitoring (TRIM) Program is associated with symptom improvement and weight reduction for patients with obesity and gastroesophageal reflux disease. Am J Gastroenterol. 2018; 113(1):23–30. doi:10.1038/ajg.2017.262.CrossRefGoogle ScholarPubMed
Harnik, IG. In the Clinic. Gastroesophageal Reflux Disease. Ann Intern Med. 2015; 163(1):ITC1. doi:10.7326/AITC201507070.CrossRefGoogle ScholarPubMed
Mc Cord, KA, Ewald, H, Agarwal, A, et al. Treatment effects in randomised trials using routinely collected data for outcome assessment versus traditional trials: Meta-research study. BMJ. 2021; 372:n450. doi:10.1136/bmj.n450.Google ScholarPubMed
References
Navar, AM. Fear-based medical misinformation and disease prevention: From vaccines to statins. JAMA Cardiol. 2019; 4(8):723–724.CrossRefGoogle ScholarPubMed
Mortensen, MB, Tybjærg-Hansen, A, Nordestgaard, BG. Statin eligibility for primary prevention of cardiovascular disease according to 2021 European prevention guidelines compared with other international guidelines. JAMA Cardiol. 2022; 7(8):836–843.CrossRefGoogle ScholarPubMed
Vernon, ST, Coffey, S, Bhindi, R, et al. Increasing proportion of ST elevation myocardial infarction patients with coronary atherosclerosis poorly explained by standard modifiable risk factors. Eur J Prev Cardiol. 2017; 24(17):1824–1830.CrossRefGoogle ScholarPubMed
Sadowitz, B, Maier, KG, Gahtan, V. Basic science review: Statin therapy-Part I: The pleiotropic effects of statins in cardiovascular disease. Vasc Endovasc Surg. 2010; 44(4):241–251.CrossRefGoogle ScholarPubMed
Calvert, GD. A review of observational studies on the relationship between cholesterol and coronary heart disease. Aust N Z J Med. 1994; 24(1):89–91.CrossRefGoogle ScholarPubMed
Ridker, PM, Mora, S, Rose, L. Percent reduction in LDL cholesterol following high-intensity statin therapy: Potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J. 2016; 37(17):1373–1379.CrossRefGoogle ScholarPubMed
Vrecer, M, Turk, S, Drinovec, J, Mrhar, A. Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke: Meta-analysis of randomized trials. Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. Centre for Reviews and Dissemination (UK); 2003.CrossRefGoogle Scholar
Pencina, MJ, Navar-Boggan, AM, D’Agostino, RB, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014; 370:1422–1431.CrossRefGoogle ScholarPubMed
Chou, R, Cantor, A, Dana, T, Wagner, J, Ahmed, A, Fu, R, Ferencik, M. Statin use for the primary prevention of cardiovascular disease in adults: A systematic review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 219. AHRQ Publication No. 22-05291-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2022.Google Scholar
Byrne, P, Demasi, M, Jones, M, Smith, SM, O’Brien, KK, DuBroff, R. Evaluating the association between low-density lipoprotein cholesterol reduction and relative and absolute effects of statin treatment: A systematic review and meta-analysis. JAMA Intern. Med. 2022; 182(5):474–481.CrossRefGoogle ScholarPubMed
Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010; 376(9753):1670–1681.CrossRefGoogle Scholar
Kristensen, ML, Christensen, PM, Hallas, J. The effect of statins on average survival in randomised trials, an analysis of end point postponement. BMJ Open. 2015; 5(9):e007118.CrossRefGoogle ScholarPubMed
Vega, GL, Grundy, SM. Current trends in non–HDL cholesterol and LDL cholesterol levels in adults with atherosclerotic cardiovascular disease. J Clin Lipidol. 2019; 13(4):563–567.CrossRefGoogle ScholarPubMed
Abramson, J, Kaplan, RM, Redberg, RF. Questioning the benefit of statins for low-risk populations – Medical misinformation or scientific evidence? JAMA Cardiol. 2020; 5(2):233.CrossRefGoogle ScholarPubMed
Incorrect Data in Text, Table, Figure, and Supplement. JAMA. 2020; 323(7):669–670. doi:10.1001/jama.2020.0182.Google Scholar
Pagidipati, NJ, Navar, AM, Mulder, H, Sniderman, AD, Peterson, ED, Pencina, MJ. Comparison of recommended eligibility for primary prevention statin therapy based on the US Preventive Services Task Force recommendations vs the ACC/AHA guidelines. JAMA. 2017; 317(15):1563–1567.CrossRefGoogle ScholarPubMed
Taylor, F, Ward, K, Moore, TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011; 1.Google Scholar
Abramson, JD, Rosenberg, HG, Jewell, N, Wright, JM. Should people at low risk of cardiovascular disease take a statin? BMJ. 2013; 347:f6123.CrossRefGoogle Scholar
Abramson, J, Rosenberg, HG, Jewell, N, Wright, JM. Remediating “Lessons from the controversy over statins.” Lancet. 2017; 389(10074):1101–1102.CrossRefGoogle ScholarPubMed
Armitage, J, Baigent, C, Barnes, E, et al. Efficacy and safety of statin therapy in older people: A meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019; 393(10170):407–415.CrossRefGoogle Scholar
Diamond, D, Kendrick, M, Mascitelli, L. Exaggerated report of benefits in a flawed long term statin treatment study. BMJ. 2017; 359:j4915.Google Scholar
Vallejo-Vaz, AJ, Robertson, M, Catapano, AL, et al. LDL-cholesterol lowering for the primary prevention of cardiovascular disease among men with primary elevations of LDL-cholesterol levels of 190 mg/dL or above: Analyses from the WOSCOPS 5-year randomised trial and 20-year observational follow-up. 2017.CrossRefGoogle Scholar
Rana, JS, Tabada, GH, Solomon, MD, et al. Accuracy of the atherosclerotic cardiovascular risk equation in a large contemporary, multiethnic population. J Am Coll Cardiol. 2016; 67(18):2118–2130.CrossRefGoogle Scholar
American College of Cardiology. ASCVD Risk Estimator Plus. https://tools.acc.org/ascvd-risk-estimator-plus/#!/calculate/estimate.Google Scholar
American Heart Association. PREVENT Online Calculator. PREVENT™ Online Calculator.Google Scholar
Krumholz, HM, Seeman, TE, Merrill, SS, et al. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA. 1994; 272(17):1335–1340.CrossRefGoogle ScholarPubMed
Liu, Y, Liu, F, Zhang, L, et al. Association between low density lipoprotein cholesterol and all-cause mortality: Results from the NHANES 1999–2014. Sci Rep. 2021; 11(1):1–12.Google ScholarPubMed
Orkaby, AR, Driver, JA, Ho, Y-L, et al. Association of statin use with all-cause and cardiovascular mortality in US veterans 75 years and older. JAMA. 2020; 324(1):68–78.CrossRefGoogle ScholarPubMed
Mortensen, MB, Falk, E. Primary prevention with statins in the elderly. J Am Coll Cardiol. 2018; 71(1):85–94.CrossRefGoogle ScholarPubMed
Gencer, B, Marston, NA, Im, K, et al. Efficacy and safety of lowering LDL cholesterol in older patients: A systematic review and meta-analysis of randomised controlled trials. Lancet. 2020; 396(10263):1637–1643.CrossRefGoogle ScholarPubMed
Cheung, BM, Lam, KS. Never too old for statin treatment? Lancet. 2019; 393(10170):379–380.CrossRefGoogle ScholarPubMed
Minemyer, P. Accessed March 16, 2024, 2024. www.fiercehealthcare.com/hospitals-health-systems/ihi-2018-don-berwick-how-providers-can-start-to-get-at-social-determinantsGoogle Scholar
Do Raymond, C, Cho, L. New cholesterol guidelines: Worth the wait? Cleve Clin J Med. 2014; 81(1):11.CrossRefGoogle ScholarPubMed
Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: A meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. Lancet. 2007; 370(9602):1829–1839.CrossRefGoogle Scholar
Leibowitz, M, Karpati, T, Cohen-Stavi, CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic heart disease taking statin treatment. JAMA Intern Med. 2016; 176(8):1105–1113.CrossRefGoogle ScholarPubMed
References
Sung, H, Ferlay, J, Siegel, RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2021; 71(3):209–249.Google ScholarPubMed
Frick, C, Rumgay, H, Vignat, J, et al. Quantitative estimates of preventable and treatable deaths from 36 cancers worldwide: A population-based study. Lancet Global Health. 2023; 11(11):e1700–e1712.CrossRefGoogle ScholarPubMed
Feirman, SP, Glasser, AM, Teplitskaya, L, et al. Medical costs and quality-adjusted life years associated with smoking: A systematic review. BMC Publ Health. 2016; 16:646. doi:10.1186/s12889-016-3319-z.CrossRefGoogle ScholarPubMed
Bonfiglio, R, Scimeca, M, Mauriello, A. The impact of environmental pollution on cancer: Risk mitigation strategies to consider. Sci Total Environ. 2023; 902:166219.CrossRefGoogle ScholarPubMed
Leiter, A, Veluswamy, RR, Wisnivesky, JP. The global burden of lung cancer: Current status and future trends. Nat Rev Clin Oncol. 2023:1–16.Google ScholarPubMed
Adami, H-O, Kalager, M, Bretthauer, M. The future of cancer screening – Guided without conflicts of interest. JAMA Intern Med. 2023.CrossRefGoogle ScholarPubMed
Schwartz, LM, Woloshin, S, Fowler, FJ, Jr., Welch, HG. Enthusiasm for cancer screening in the United States. JAMA. 2004; 291(1):71–78.CrossRefGoogle ScholarPubMed
Aronowitz, RA. Do not delay: Breast cancer and time, 1900–1970. Milbank Q. 2001; 79(3):355–86, III.CrossRefGoogle Scholar
Eddy, DM. The frequency of cervical cancer screening. Comparison of a mathematical model with empirical data. Cancer. 1987; 60(5):1117–1122.3.0.CO;2-H>CrossRefGoogle ScholarPubMed
Harris, P, Carnes, M. Is there an age at which we should stop performing screening pap smears and mammography? Cleve Clin J Med. 2002; 69(4):272–273.CrossRefGoogle ScholarPubMed
Parnes, BL, Smith, PC, Conry, CM, Domke, H. When should we stop mamography screening for breast cancer in elderly women? J Fam Pract. 2001; 50(2):110–111.Google Scholar
Shapiro, S, Coleman, EA, Broeders, M, et al. Breast cancer screening programmes in 22 countries: Current policies, administration and guidelines. International Breast Cancer Screening Network (IBSN) and the European Network of Pilot Projects for Breast Cancer Screening. Int J Epidemiol. 1998; 27(5):735–742.CrossRefGoogle ScholarPubMed
Kaplan, RM. Shared medical decision making. A new tool for preventive medicine. Am J Prev Med. 2004; 26(1):81–83. doi:S0749379703003015 [pii].CrossRefGoogle ScholarPubMed
Baum, M. re: Reflections on screening mammography and the early detection of breast cancer. Curr Oncol. 2014; 21(5):215–216. doi:10.3747/co.21.2134.CrossRefGoogle ScholarPubMed
Baum, M. “Catch it early, save a life and save a breast”: This misleading mantra of mammography. J R Soc Med. 2015; 108(9):338–339. doi:10.1177/0141076815603563.CrossRefGoogle ScholarPubMed
Arie, S. Uruguay’s mandatory breast cancer screening for working women aged 40–59 is challenged. BMJ: Brit Med J (Online). 2013; 346:f1907.CrossRefGoogle ScholarPubMed
Baum, M. Harms from breast cancer screening outweigh benefits if death caused by treatment is included. BMJ. 2013; 346:f385.CrossRefGoogle ScholarPubMed
Woloshin, S, Jørgensen, KJ, Hwang, S, Welch, HG. The new USPSTF mammography recommendations – A dissenting view. N Engl J Med. 2023; 389(12):1061–1064.CrossRefGoogle ScholarPubMed
Gøtzsche, PC, Hróbjartsson, A, Johansen, HK, Haahr, MT, Altman, DG, Chan, A-W. Ghost authorship in industry-initiated randomised trials. PLoS Med. 2007; 4(1):e19.CrossRefGoogle ScholarPubMed
Jørgensen, L, Gøtzsche, PC, Jefferson, T. Benefits and harms of the human papillomavirus (HPV) vaccines: Systematic review with meta-analyses of trial data from clinical study reports. Syst Rev. 2020; 9:1–23.Google ScholarPubMed
Olsen, O, Gøtzsche, PC. Cochrane review on screening for breast cancer with mammography. Lancet. 2001; 358(9290):1340–1342.CrossRefGoogle ScholarPubMed
Venkatesan, P. New US breast cancer screening recommendations. Lancet Oncol. 2023; 24(6):e242.CrossRefGoogle ScholarPubMed
Field, JK, Duffy, SW, Baldwin, DR, et al. The UK Lung Cancer Screening Trial: A pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. Health Technol Assess. 2016; 20(40):1–146. doi:10.3310/hta20400.CrossRefGoogle Scholar
Tabar, L, Fagerberg, G, Chen, HH, et al. Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial. Cancer. 1995; 75(10):2507–2517.3.0.CO;2-H>CrossRefGoogle ScholarPubMed
Tabár, L, Vitak, B, Chen, TH-H, et al. Swedish two-county trial: Impact of mammographic screening on breast cancer mortality during 3 decades. Radiology. 2011; 260(3):658–663.CrossRefGoogle ScholarPubMed
Bleyer, A, Welch, HG. Effect of screening mammography on breast cancer incidence. N Engl J Med. 2013; 368(7):679. doi:10.1056/NEJMc1215494.Google ScholarPubMed
Harding, C, Pompei, F, Burmistrov, D, Welch, HG, Abebe, R, Wilson, R. Breast cancer screening, incidence, and mortality across US counties. JAMA Intern Med. 2015; 175(9):1483–1489. doi:10.1001/jamainternmed.2015.3043CrossRefGoogle ScholarPubMed
Welch, HG. Should I Be Tested for Cancer?: Maybe not and Here’s Why. University of California Press; 2004.CrossRefGoogle Scholar
Welch, HG. Responding to the challenge of overdiagnosis. Acad Radiol. 2015; 22(8):945–946. doi:10.1016/j.acra.2014.08.019.CrossRefGoogle Scholar
Welch, HG, Passow, HJ. Quantifying the benefits and harms of screening mammography. JAMA Intern Med. 2014; 174(3):448–454. doi:10.1001/jamainternmed.2013.13635.CrossRefGoogle ScholarPubMed
Jørgensen, KJ, Zahl, P-H, Gøtzsche, PC. Breast cancer mortality in organised mammography screening in Denmark: Comparative study. BMJ. 2010; 340:c1241.CrossRefGoogle ScholarPubMed
Junod, B, Zahl, P-H, Kaplan, RM, Olsen, J, Greenland, S. An investigation of the apparent breast cancer epidemic in France: Screening and incidence trends in birth cohorts. BMC Cancer. 2011; 11(1):1–8.CrossRefGoogle ScholarPubMed
Zahl, P-H, Maehlen, J, Welch, HG. The natural history of invasive breast cancers detected by screening mammography. Arch Intern Med. 2008; 168(21):2311–2316.CrossRefGoogle ScholarPubMed
Zahl, P-H, Strand, BH, Mæhlen, J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: Prospective cohort study. BMJ. 2004; 328(7445):921–924.CrossRefGoogle ScholarPubMed
Keen, JD, Jorgensen, KJ. Four principles to consider before advising women on screening mammography. J Womens Health (Larchmt). 2015. doi:10.1089/jwh.2015.5220.CrossRefGoogle ScholarPubMed
Bretthauer, M, Wieszczy, P, Løberg, M, et al. Estimated lifetime gained with cancer screening tests: A meta-analysis of randomized clinical trials. JAMA Intern Med. 2023; 183(11):1196–1203.CrossRefGoogle ScholarPubMed
Bleyer, A, Welch, HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012; 367(21):1998–2005. doi:10.1056/NEJMoa1206809.CrossRefGoogle ScholarPubMed
Sakorafas, GH. The origins of radical mastectomy. AORN J. 2008; 88(4):605–608.CrossRefGoogle ScholarPubMed
Muhkerjee, S. The Emperor of All Maladies: A Biography of Cancer. Scribner: A Division of Simon and Schuster; 2011.Google Scholar
Singh, R, Hellman, S, Heimann, R. The natural history of breast carcinoma in the elderly: Implications for screening and treatment. Cancer. 2004; 100(9):1807–1813. doi:10.1002/cncr.20206.CrossRefGoogle ScholarPubMed
Welch, HG, Gorski, DH, Albertsen, PC. Trends in metastatic breast and prostate cancer – Lessons in cancer dynamics. N Engl J Med. 2015; 373(18):1685–1687. doi:10.1056/NEJMp1510443.CrossRefGoogle ScholarPubMed
Fisher, B, Anderson, S, Bryant, J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002; 347(16):1233–1241.CrossRefGoogle ScholarPubMed
Hellman, S. Karnofsky Memorial Lecture. Natural history of small breast cancers. J Clin Oncol. 1994; 12(10):2229–2234.CrossRefGoogle ScholarPubMed
Welch, HG. The heterogeneity of cancer. Breast Cancer Res Treat. 2018; 169(2):207–208. doi:10.1007/s10549-018-4691-4CrossRefGoogle ScholarPubMed
Black, WC, Welch, HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med. 1993; 328(17):1237–1243.CrossRefGoogle ScholarPubMed
Ma, T, Semsarian, CR, Barratt, A, et al. Should low-risk DCIS lose the cancer label? An evidence review. Breast Cancer Res Treat. 2023; 199(3):415–433.CrossRefGoogle ScholarPubMed
Esserman, LJ, Thompson, IM, Jr., Reid, B. Overdiagnosis and overtreatment in cancer: An opportunity for improvement. JAMA. 2013; 310(8):797–798. doi:10.1001/jama.2013.108415.CrossRefGoogle ScholarPubMed
Chidiac, RM, Aron, DC. Incidentalomas: A disease of modern technology. Endocrinol Metabol Clin. 1997; 26(1):233–253.CrossRefGoogle ScholarPubMed
Black, WC, Welch, HG. Screening for disease. AJR Am J Roentgenol. 1997; 168(1):3–11.CrossRefGoogle ScholarPubMed
Welch, HG, Black, WC. Evaluating randomized trials of screening. J Gen Intern Med. 1997; 12(2):118–124.CrossRefGoogle ScholarPubMed
American Cancer Society. California Division., California Cancer Registry. California cancer facts & figures. Oakland, CA: American Cancer Society California Division. p. v.Google Scholar
Ansari, KK, Jha, A. Causes of cancer in the world: Comparative risk assessment of nine behavioral and environmental risk factors. Cureus. 2022; 14(9).Google ScholarPubMed
Barratt, A, Howard, K, Irwig, L, Salkeld, G, Houssami, N. Model of outcomes of screening mammography: Information to support informed choices. BMJ. 2005; 330(7497):936.CrossRefGoogle ScholarPubMed
Zahl, P, Mæhlen, J, Welch, H. Arch Intern Med. 2008; 168(21):2311–2316. doi:10.1001/archinte.168.21.2311.CrossRefGoogle Scholar
Zahl, PH, Maehlen, J. Model of outcomes of screening mammography: Spontaneous regression of breast cancer may not be uncommon. BMJ. 2005; 331(7512):350; author reply 351.CrossRefGoogle Scholar
Baum, M, Demicheli, R, Hrushesky, W, Retsky, M. Does surgery unfavourably perturb the “natural history” of early breast cancer by accelerating the appearance of distant metastases? Eur J Cancer. 2005; 41(4):508–515.CrossRefGoogle ScholarPubMed
Canadian Task Force on Preventative Health Care. Recommendations on screening for breast cancer in average-risk women aged 40–74 years. CMAJ. 2011; 183(17):1991–2001.CrossRefGoogle Scholar
Marmot, MG, Altman, D, Cameron, D, Dewar, J, Thompson, S, Wilcox, M. The benefits and harms of breast cancer screening: An independent review. Br J Cancer. 2013; 108(11):2205–2240.CrossRefGoogle ScholarPubMed
Canelo-Aybar, C, Ferreira, DS, Ballesteros, M, et al. Benefits and harms of breast cancer mammography screening for women at average risk of breast cancer: A systematic review for the European Commission Initiative on Breast Cancer. J Med Screening. 2021; 28(4):389–404.CrossRefGoogle ScholarPubMed
Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Working Group. Breast cancer screening with mammography: An updated decision analysis for the U.S. Preventive Services Task Force. 2023. www.uspreventiveservicestaskforce.org/uspstf/document/draft-modeling-report/breast-cancer-screening-adults.Google Scholar
Henderson, J, Webbe, EM, Weiyrich, M, Miller, M, Melnikow, J. Screening for breast cancer: A comparative effectiveness review for the U.S. Preventive Services Task Force. 2023. www.uspreventiveservicestaskforce.org/uspstf/document/draft-evidence-review/breast-cancer-screening-adults.CrossRefGoogle Scholar
Irvin, VL, Kaplan, RM. Screening mammography & breast cancer mortality: Meta-analysis of quasi-experimental studies. PloS One. 2014; 9(6):e98105.CrossRefGoogle ScholarPubMed
Nelson, HD, Pappas, M, Cantor, A, Griffin, J, Daeges, M, Humphrey, L. Harms of breast cancer screening: Systematic review to update the 2009 US Preventive Services Task Force recommendation. Ann Intern Med. 2016; 164(4):256–267.CrossRefGoogle ScholarPubMed
Nelson, HD, Cantor, A, Humphrey, L, Fu, R, Pappas, M, Daeges, M, Griffin, J. Screening for breast cancer: A systematic review to update the 2009 U.S. Preventive Services Task Force Recommendation. Evidence Synthesis No. 124. AHRQ Publication No. 14-05201-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2016.Google Scholar
Tabar, L, Gad, A, Holmberg, L, et al. Reduction in mortality from breast cancer after mass screening with mammography: Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet. 1985; 325(8433):829–832.CrossRefGoogle Scholar
Vo, JB, Ramin, C, Barac, A, Berrington de Gonzalez, A, Veiga, L. Trends in heart disease mortality among breast cancer survivors in the US, 1975–2017. Breast Cancer Res Treat. 2022; 192(3):611–622.CrossRefGoogle ScholarPubMed
Kerr, AJ, Dodwell, D, McGale, P, et al. Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality. Cancer Treat Rev. 2022; 105:102375.CrossRefGoogle ScholarPubMed
Canadian Broadcasting Company. Ontario to lower age for regular breast cancer screenings to 40. www.cbc.ca/news/canada/toronto/ontario-breast-cancer-screening-1.7012294.Google Scholar
Woloshin, S, Jørgensen, KJ, Hwang, S, Welch, HG. The new USPSTF mammography recommendations – A dissenting view. N Engl J Med. 2023; 389(12):1061–1064.CrossRefGoogle ScholarPubMed
Pearl, J, Mackenzie, D. The Book of Why: The New Science of Cause and Effect. Basic Books; 2018.Google Scholar
Lehman, CD, Wellman, RD, Buist, DS, et al. Diagnostic accuracy of digital screening mammography with and without computer-aided detection. JAMA Intern Med. 2015; 175(11):1828–1837. doi:10.1001/jamainternmed.2015.5231.CrossRefGoogle ScholarPubMed
Fenton, JJ. Is it time to stop paying for computer-aided mammography? JAMA Intern Med. 2015; 175(11):1837–1838. doi:10.1001/jamainternmed.2015.5319.CrossRefGoogle ScholarPubMed
Jatoi, I, Sung, H, Jemal, A. The emergence of the racial disparity in US breast-cancer mortality. N Engl J Med. 2022; 386(25):2349–2352.CrossRefGoogle ScholarPubMed
Yedjou, CG, Sims, JN, Miele, L, et al. Health and racial disparity in breast cancer. Breast Cancer Metastasis Drug Resist: Challenges Progress. 2019:31–49.CrossRefGoogle ScholarPubMed
Bell, N, Gorber, SC, Shane, A, et al. Recommendations on screening for prostate cancer with the prostate-specific antigen test. CMAJ. 2014; 186(16):1225–1234.CrossRefGoogle ScholarPubMed
Lin, K, Lipsitz, R, Miller, T, Janakiraman, S. Benefits and harms of prostate-specific antigen screening for prostate cancer: An evidence update for the US Preventive Services Task Force. Ann Intern Med. 2008; 149(3):192–199.CrossRefGoogle Scholar
Bretthauer, M, Løberg, M, Wieszczy, P, et al. Effect of colonoscopy screening on risks of colorectal cancer and related death. N Engl J Med. 2022; 387(17):1547–1556.CrossRefGoogle ScholarPubMed
Rose, SL, Highland, J, Karafa, MT, Joffe, S. Patient advocacy organizations, industry funding, and conflicts of interest. JAMA Intern Med. 2017; 177(3):344–350.CrossRefGoogle ScholarPubMed
Richman, IB, Long, JB, Soulos, PR, Wang, S-Y, Gross, CP. Estimating breast cancer overdiagnosis after screening mammography among older women in the United States. Ann Intern Med. 2023; 176(9):1172–1180.CrossRefGoogle ScholarPubMed
Sheehan, L, Corrigan, P. Stigma of disease and its impact on health. Wiley Encyclopedia Health Psychol. 2020:57–65.CrossRefGoogle Scholar
Jacobs, JE, L’Hoyes, W, Lauwens, L, et al. Mortality and major adverse cardiac events in patients with breast cancer receiving radiotherapy: The first decade. J Am Heart Assoc. 2023; 12(8):e027855.CrossRefGoogle ScholarPubMed
McCoy, MS, Carniol, M, Chockley, K, Urwin, JW, Emanuel, EJ, Schmidt, H. Conflicts of interest for patient-advocacy organizations. N Engl J Med. 2017; 376(9):880–885.CrossRefGoogle ScholarPubMed
Halpern, MT, Liu, B, Lowy, DR, Gupta, S, Croswell, JM, Doria-Rose, VP. The annual cost of cancer screening in the United States. Ann Intern Med. 2024. doi:10.7326/M24-0375.CrossRefGoogle ScholarPubMed
Leapman, MS, Wang, R, Park, H, et al. Changes in prostate-specific antigen testing relative to the revised US Preventive Services Task Force recommendation on prostate cancer screening. JAMA Oncol. 2022; 8(1):41–47.CrossRefGoogle Scholar
Burgess, L, Aldrighetti, CM, Ghosh, A, et al. Association of the USPSTF grade D recommendation against prostate-specific antigen screening with prostate cancer–specific mortality. JAMA Netw Open. 2022; 5(5):e2211869–e2211869.CrossRefGoogle Scholar
Welch, HG. Dollars and sense: The cost of cancer screening in the United States. Ann Intern Med. 2024. doi:10.7326/M24-0887.CrossRefGoogle ScholarPubMed
References
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5-TR. 5th ed, text revision. ed. American Psychiatric Association Publishing; 2022:1 online resource.Google Scholar
Kessler, RC, Berglund, P, Demler, O, et al. The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003; 289(23):3095–3105. doi:10.1001/jama.289.23.3095.CrossRefGoogle ScholarPubMed
Almohammed, OA, Alsalem, AA, Almangour, AA, Alotaibi, LH, Al Yami, MS, Lai, L. Antidepressants and health-related quality of life (HRQoL) for patients with depression: Analysis of the medical expenditure panel survey from the United States. PLoS One. 2022; 17(4):e0265928. doi:10.1371/journal.pone.0265928.CrossRefGoogle ScholarPubMed
Patten, SB. Accumulation of major depressive episodes over time in a prospective study indicates that retrospectively assessed lifetime prevalence estimates are too low. BMC Psychiat. 2009; 9:19. doi:10.1186/1471-244X-9-19.CrossRefGoogle Scholar
Liu, Q, He, H, Yang, J, Feng, X, Zhao, F, Lyu, J. Changes in the global burden of depression from 1990 to 2017: Findings from the Global Burden of Disease study. J Psychiatr Res. 2020; 126:134–140. doi:10.1016/j.jpsychires.2019.08.002.CrossRefGoogle ScholarPubMed
Global Burden of Disease 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396(10258):1204–1222. doi:10.1016/S0140-6736(20)30925-9.CrossRefGoogle Scholar
Cuijpers, P, Vogelzangs, N, Twisk, J, Kleiboer, A, Li, J, Penninx, BW. Comprehensive meta-analysis of excess mortality in depression in the general community versus patients with specific illnesses. Am J Psychiatry. 2014; 171(4):453–462. doi:10.1176/appi.ajp.2013.13030325.CrossRefGoogle ScholarPubMed
Cuijpers, P, Vogelzangs, N, Twisk, J, Kleiboer, A, Li, J, Penninx, BW. Is excess mortality higher in depressed men than in depressed women? A meta-analytic comparison. J Affect Disord. 2014; 161:47–54. doi:10.1016/j.jad.2014.03.003.CrossRefGoogle ScholarPubMed
Machado, MO, Veronese, N, Sanches, M, et al. The association of depression and all-cause and cause-specific mortality: An umbrella review of systematic reviews and meta-analyses. BMC Med. 2018; 16(1):112. doi:10.1186/s12916-018-1101-z.CrossRefGoogle ScholarPubMed
Siu, AL, Bibbins-Domingo, K, Grossman, DC, et al. Screening for depression in adults: US preventive services task force recommendation statement. JAMA. 2016; 315(4):380–387. doi:10.1001/jama.2015.18392.CrossRefGoogle ScholarPubMed
Kroenke, K, Spitzer, RL, Williams, JB. The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med. 2001; 16(9):606–613. doi:10.1046/j.1525-1497.2001.016009606.x.CrossRefGoogle ScholarPubMed
Eaton, WW, Shao, H, Nestadt, G, Lee, HB, Bienvenu, OJ, Zandi, P. Population-based study of first onset and chronicity in major depressive disorder. Arch Gen Psychiatry. 2008; 65(5):513–520. doi:10.1001/archpsyc.65.5.513.CrossRefGoogle ScholarPubMed
Solomon, DA, Keller, MB, Leon, AC, et al. Recovery from major depression. A 10-year prospective follow-up across multiple episodes. Arch Gen Psychiatry. 1997; 54(11):1001–1006. doi:10.1001/archpsyc.1997.01830230033005.CrossRefGoogle ScholarPubMed
Kovacs, M, Obrosky, S, George, C. The course of major depressive disorder from childhood to young adulthood: Recovery and recurrence in a longitudinal observational study. J Affect Disord. 2016; 203:374–381. doi:10.1016/j.jad.2016.05.042.CrossRefGoogle Scholar
Coryell, W, Akiskal, HS, Leon, AC, et al. The time course of nonchronic major depressive disorder. Uniformity across episodes and samples. National Institute of Mental Health Collaborative Program on the Psychobiology of Depression – Clinical Studies. Arch Gen Psychiatry. 1994; 51(5):405–410. doi:10.1001/archpsyc.1994.03950050065007.CrossRefGoogle ScholarPubMed
Coryell, W, Solomon, D, Leon, A, et al. Does major depressive disorder change with age? Psychol Med. 2009; 39(10):1689–1695. doi:10.1017/S0033291709005364.CrossRefGoogle ScholarPubMed
Thase, ME. Long-term nature of depression. J Clin Psychiatry. 1999; 60(Suppl 14):3–9; discussion 31–35.Google ScholarPubMed
Judd, LL, Akiskal, HS, Paulus, MP. The role and clinical significance of subsyndromal depressive symptoms (SSD) in unipolar major depressive disorder. J Affect Disord. 1997; 45(1–2):5–17; discussion 17–18. doi:10.1016/s0165-0327(97)00055-4.CrossRefGoogle ScholarPubMed
National Health Service. Medicines Used in Mental Health: England 2015/16 to 2020/21. Updated July 8, 2021. https://nhsbsa-opendata.s3.eu-west-2.amazonaws.com/mumh/mumh_annual_2020_21_v001.html.Google Scholar
Brody, DJ, Gu, Q. Antidepressant use among adults: United States, 2015–2018. NCHS Data Brief. 2020; (377):1–8.Google Scholar
Pratt, LA, Brody, DJ, Gu, Q. Antidepressant use among persons aged 12 and over: United States, 2011–2014. NCHS Data Brief. 2017; 283):1–8.Google Scholar
Centers for Disease Control and Prevention. Health, United States, 2016 – Individual Charts and Tables: Spreadsheet, PDF, and PowerPoint files. Table 80. Selected prescription drug classes used in the past 30 days, by sex and age: United States, selected years 1988–1994 through 2011–2014. 2016. www.cdc.gov/nchs/data/hus/2016/080.pdf.Google Scholar
Centers for Disease Control and Prevention. National Ambulatory Medical Care Survey: 2019 National Summary Tables. Table 22. Twenty most frequently mentioned drugs at office visits, by therapeutic drug category: United States, 2019. 2019. www.cdc.gov/nchs/data/ahcd/namcs_summary/2019-namcs-web-tables-508.pdf.Google Scholar
Centers for Disease Control and Prevention. NHANES Response Rates and Population Totals. Accessed April 19, 2024, wwwn.cdc.gov/nchs/nhanes/responserates.aspx#population-totals.Google Scholar
Luo, Y, Kataoka, Y, Ostinelli, EG, Cipriani, A, Furukawa, TA. National prescription patterns of antidepressants in the treatment of adults with major depression in the US between 1996 and 2015: A population representative survey based analysis. Front Psychiatry. 2020; 11:35. doi:10.3389/fpsyt.2020.00035.CrossRefGoogle ScholarPubMed
Gorfinkel, LR, Hasin, D, Saxon, AJ, et al. Trends in prescriptions for non-opioid pain medications among U.S. adults with moderate or severe pain, 2014–2018. J Pain. 2022; 23(7):1187–1195. doi:10.1016/j.jpain.2022.01.006.CrossRefGoogle ScholarPubMed
Wong, J, Motulsky, A, Abrahamowicz, M, Eguale, T, Buckeridge, DL, Tamblyn, R. Off-label indications for antidepressants in primary care: Descriptive study of prescriptions from an indication based electronic prescribing system. BMJ. 2017; 356:j603. doi:10.1136/bmj.j603.Google ScholarPubMed
Mojtabai, R, Olfson, M. Proportion of antidepressants prescribed without a psychiatric diagnosis is growing. Health Aff (Millwood). 2011; 30(8):1434–1442. doi:10.1377/hlthaff.2010.1024.CrossRefGoogle ScholarPubMed
Radley, DC, Finkelstein, SN, Stafford, RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006; 166(9):1021–1026. doi:10.1001/archinte.166.9.1021.CrossRefGoogle ScholarPubMed
Mercier, A, Auger-Aubin, I, Lebeau, JP, et al. Evidence of prescription of antidepressants for non-psychiatric conditions in primary care: An analysis of guidelines and systematic reviews. BMC Fam Pract. 2013; 14:55. doi:10.1186/1471-2296-14-55.CrossRefGoogle ScholarPubMed
Lim, D, Jung, J. Racial-ethnic differences in off-label antidepressant use, by insurance type. Psychiatr Serv. 2017; 68(12):1271–1279. doi:10.1176/appi.ps.201600445.CrossRefGoogle ScholarPubMed
Food and Drug Administration. Suicidality in children and adolescents being treated with antidepressant medications. 2004. PMID:30844209.Google Scholar
Friedman, RA. Antidepressants’ black-box warning – 10 years later. N Engl J Med. 2014; 371(18):1666–1668. doi:10.1056/NEJMp1408480.CrossRefGoogle ScholarPubMed
Spielmans, GI, Spence-Sing, T, Parry, P. Duty to warn: Antidepressant black box suicidality warning is empirically justified. Front Psychiatry. 2020; 11:18. doi:10.3389/fpsyt.2020.00018.CrossRefGoogle ScholarPubMed
Scotton, WJ, Hill, LJ, Williams, AC, Barnes, NM. Serotonin syndrome: Pathophysiology, clinical features, management, and potential future directions. Int J Tryptophan Res. 2019; 12:1178646919873925. doi:10.1177/1178646919873925.CrossRefGoogle ScholarPubMed
Schatzberg, AF, Haddad, P, Kaplan, EM, et al. Serotonin reuptake inhibitor discontinuation syndrome: A hypothetical definition. Discontinuation consensus panel. J Clin Psychiatry. 1997; 58(Suppl 7):5–10.Google ScholarPubMed
Dragioti, E, Solmi, M, Favaro, A, et al. Association of antidepressant use with adverse health outcomes: A systematic umbrella review. JAMA Psychiatry. 2019; 76(12):1241–1255. doi:10.1001/jamapsychiatry.2019.2859.CrossRefGoogle ScholarPubMed
Marazziti, D, Mucci, F, Tripodi, B, et al. Emotional blunting, cognitive impairment, bone fractures, and bleeding as possible side effects of long-term use of SSRIs. Clin Neuropsychiatry. 2019; 16(2):75–85.Google ScholarPubMed
Coupland, C, Dhiman, P, Morriss, R, Arthur, A, Barton, G, Hippisley-Cox, J. Antidepressant use and risk of adverse outcomes in older people: Population based cohort study. BMJ. 2011; 343:d4551. doi:10.1136/bmj.d4551.CrossRefGoogle ScholarPubMed
Coupland, C, Hill, T, Morriss, R, Moore, M, Arthur, A, Hippisley-Cox, J. Antidepressant use and risk of adverse outcomes in people aged 20–64 years: Cohort study using a primary care database. BMC Med. 2018; 16(1):36. doi:10.1186/s12916-018-1022-x.CrossRefGoogle ScholarPubMed
Mojtabai, R, Olfson, M. National trends in long-term use of antidepressant medications: Results from the U.S. National Health and Nutrition Examination Survey. J Clin Psychiatry. 2014; 75(2):169–177. doi:10.4088/JCP.13m08443.CrossRefGoogle ScholarPubMed
Moncrieff, J, Cooper, RE, Stockmann, T, Amendola, S, Hengartner, MP, Horowitz, MA. The serotonin theory of depression: A systematic umbrella review of the evidence. Mol Psychiatry. 2022; doi:10.1038/s41380-022-01661-0.Google ScholarPubMed
Stone, MB, Yaseen, ZS, Miller, BJ, Richardville, K, Kalaria, SN, Kirsch, I. Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US Food and Drug Administration: Individual participant data analysis. BMJ. 2022; 378:e067606. doi:10.1136/bmj-2021-067606.Google Scholar
Turner, EH, Cipriani, A, Furukawa, TA, Salanti, G, de Vries, YA. Selective publication of antidepressant trials and its influence on apparent efficacy: Updated comparisons and meta-analyses of newer versus older trials. PLoS Med. 2022; 19(1):e1003886. doi:10.1371/journal.pmed.1003886.CrossRefGoogle ScholarPubMed
Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23(1):56–62. doi:10.1136/jnnp.23.1.56.CrossRefGoogle ScholarPubMed
Furukawa, TA, Cipriani, A, Atkinson, LZ, et al. Placebo response rates in antidepressant trials: A systematic review of published and unpublished double-blind randomised controlled studies. Lancet Psychiatry. 2016; 3(11):1059–1066. doi:10.1016/S2215-0366(16)30307-8.CrossRefGoogle ScholarPubMed
de Vries, YA, Roest, AM, de Jonge, P, Cuijpers, P, Munafò, MR, Bastiaansen, JA. The cumulative effect of reporting and citation biases on the apparent efficacy of treatments: The case of depression. Psychol Med. 2018; 48(15):2453–2455. doi:10.1017/S0033291718001873.CrossRefGoogle ScholarPubMed
Kazdin, AE. Treatment as usual and routine care in research and clinical practice. Clin Psychol Rev. 2015; 42:168–178. doi:10.1016/j.cpr.2015.08.006.CrossRefGoogle ScholarPubMed
Cuijpers, P, Miguel, C, Ciharova, M, et al. Psychological treatment of depression with other comorbid mental disorders: Systematic review and meta-analysis. Cogn Behav Ther. 2023:1–23. doi:10.1080/16506073.2023.2166578.Google ScholarPubMed
Westen, D, Morrison, K. A multidimensional meta-analysis of treatments for depression, panic, and generalized anxiety disorder: An empirical examination of the status of empirically supported therapies. J Consult Clin Psychol. 2001; 69(6):875–899.CrossRefGoogle ScholarPubMed
Lorenzo-Luaces, L, Zimmerman, M, Cuijpers, P. Are studies of psychotherapies for depression more or less generalizable than studies of antidepressants? J Affect Disord. 2018; 234:8–13. doi:10.1016/j.jad.2018.02.066.CrossRefGoogle ScholarPubMed
Kessler, RC, Birnbaum, HG, Shahly, V, et al. Age differences in the prevalence and co-morbidity of DSM-IV major depressive episodes: Results from the WHO World Mental Health Survey Initiative. Depress Anxiety. 2010; 27(4):351–364. doi:10.1002/da.20634.CrossRefGoogle ScholarPubMed
Zimmerman, M, Balling, C, Chelminski, I, Dalrymple, K. Applying the inclusion/exclusion criteria in placebo-controlled studies to a clinical sample: A comparison of medications. J Affect Disord. 2020; 260:483–488. doi:10.1016/j.jad.2019.09.012.CrossRefGoogle Scholar
Rush, AJ, Fava, M, Wisniewski, SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design. Control Clin Trials. 2004; 25(1):119–142. doi:10.1016/s0197-2456(03)00112-0.CrossRefGoogle Scholar
van der Lem, R, de Wever, WW, van der Wee, NJ, van Veen, T, Cuijpers, P, Zitman, FG. The generalizability of psychotherapy efficacy trials in major depressive disorder: An analysis of the influence of patient selection in efficacy trials on symptom outcome in daily practice. BMC Psychiatry. 2012; 12:192. doi:10.1186/1471-244X-12-192.CrossRefGoogle ScholarPubMed
Zimmerman, M, Clark, HL, Multach, MD, Walsh, E, Rosenstein, LK, Gazarian, D. Have treatment studies of depression become even less generalizable? A review of the inclusion and exclusion criteria used in Placebo-controlled antidepressant efficacy trials published during the past 20 years. Mayo Clin Proc. 2015; 90(9):1180–1186. doi:10.1016/j.mayocp.2015.06.016.CrossRefGoogle ScholarPubMed
Judd, LL, Paulus, MP, Wells, KB, Rapaport, MH. Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population. Am J Psychiatry. 1996; 153(11):1411–1417. doi:10.1176/ajp.153.11.1411.Google Scholar
Pietrzak, RH, Kinley, J, Afifi, TO, Enns, MW, Fawcett, J, Sareen, J. Subsyndromal depression in the United States: Prevalence, course, and risk for incident psychiatric outcomes. Psychological Medicine. 2013; 43:1401–1414. doi: 10.1017/S0033291712002309.CrossRefGoogle ScholarPubMed
Centers for Disease Control and Prevention. Distribution of the civilian noninstitutionalized population for 2017–2018 by gender, age, and race/ethnicity domains. wwwn.cdc.gov/nchs/data/nhanes3/ResponseRates/ACS-Population-Totals-For-2017-2018-508.pdf.Google Scholar
Kessler, RC, Chiu, WT, Demler, O, Merikangas, KR, Walters, EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62(6):617–627. doi:10.1001/archpsyc.62.6.617.CrossRefGoogle ScholarPubMed
Cuijpers, P, Ciharova, M, Quero, S, et al. The contribution of “Individual Participant Data” meta-analyses of psychotherapies for depression to the development of personalized treatments: A systematic review. J Pers Med. 2022; 12(1). doi:10.3390/jpm12010093.CrossRefGoogle Scholar
Ünlü Ince, B, Riper, H, van’t Hof, E, Cuijpers, P. The effects of psychotherapy on depression among racial-ethnic minority groups: A metaregression analysis. Psychiatr Serv. 2014; 65(5):612–617. doi:10.1176/appi.ps.201300165.CrossRefGoogle ScholarPubMed
Amati, F, Green, J, Kitchin, L, et al. Ethnicity as a predictor of outcomes of psychological therapies for anxiety and depression: A retrospective cohort analysis. Behav Cogn Psychother. 2023; 51(2):164–173. doi:10.1017/S1352465822000558.CrossRefGoogle ScholarPubMed
Puyat, JH, Kazanjian, A, Goldner, EM, Wong, H. How often do individuals with major depression receive minimally adequate treatment? A population-based, data linkage study. Can J Psychiatry. 2016; 61(7):394–404.CrossRefGoogle Scholar
Prien, RF, Kupfer, DJ. Continuation drug therapy for major depressive episodes: How long should it be maintained? Am J Psychiatry. 1986; 143(1):18–23. doi:10.1176/ajp.143.1.18.Google ScholarPubMed
Lewis, G, Marston, L, Duffy, L, et al. Maintenance or discontinuation of antidepressants in primary care. N Engl J Med. 2021; 385(14):1257–1267. doi:10.1056/NEJMoa2106356.CrossRefGoogle ScholarPubMed
Pigott, HE, Leventhal, AM, Alter, GS, Boren, JJ. Efficacy and effectiveness of antidepressants: Current status of research. Psychother Psychosom. 2010; 79(5):267–279. doi:10.1159/000318293.CrossRefGoogle ScholarPubMed
Montgomery, SA, Asberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134:382–389. doi:10.1192/bjp.134.4.382.CrossRefGoogle ScholarPubMed
Nierenberg, AA, DeCecco, LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: A focus on treatment-resistant depression. J Clin Psychiatry. 2001; 62(Suppl 16):5–9.Google ScholarPubMed
Moncrieff, J, Kirsch, I. Empirically derived criteria cast doubt on the clinical significance of antidepressant-placebo differences. Contemp Clin Trials. 2015; 43:60–62. doi:10.1016/j.cct.2015.05.005.CrossRefGoogle ScholarPubMed
Cummergen, K, Hannah, L, Jopling, L, Cameron, R, Walsh, C, Perez, J. What outcomes matter to service users who experience persistent depression: A mixed-method narrative review and synthesis. J Affect Disorder Rep. 2022; 10. doi:10.1016/j.jadr.2022.100431.Google Scholar
Shah, D, Vaidya, V, Patel, A, Borovicka, M, Goodman, MH. Assessment of health-related quality of life, mental health status and psychological distress based on the type of pharmacotherapy used among patients with depression. Qual Life Res. 2017; 26(4):969–980. doi:10.1007/s11136-016-1417-0.CrossRefGoogle ScholarPubMed
Keller, MB, Ryan, ND, Strober, M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: A randomized, controlled trial. J Am Acad Child Adolesc Psychiatry. 2001; 40(7):762–772. doi:10.1097/00004583-200107000-00010.CrossRefGoogle ScholarPubMed
SmithKlineBeecham Pharmaceuticals. Protocol 29060/329: A multi-center, double-blind, placebo controlled study of paroxetine and imipramine in adolescents with unipolar major depression. 1996. www.gsk.com/media/1520/appendix-a.pdf.Google Scholar
McHenry, LB, Jureidini, JN. Industry-sponsored ghostwriting in clinical trial reporting: A case study. Account Res. 2008; 15(3):152–167. doi:10.1080/08989620802194384.CrossRefGoogle ScholarPubMed
Allen, L, Scott, J, Brand, A, Hlava, M, Altman, M. Publishing: Credit where credit is due. Nature. 2014; 508(7496):312–313. doi:10.1038/508312a.CrossRefGoogle ScholarPubMed
Ethical Principles of Psychologists and Code of Conduct. Am Psychol. 1992; 47(12):1597–1611. doi:10.1037/0003-066X.47.12.1597.CrossRefGoogle Scholar
Le Noury, J, Nardo, JM, Healy, D, et al. Restoring Study 329: Efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ. 2015; 351:h4320. doi:10.1136/bmj.h4320.Google ScholarPubMed
Le Noury, J, Nardo, JM, Healy, D, et al. Study 329 continuation phase: Safety and efficacy of paroxetine and imipramine in extended treatment of adolescent major depression. Int J Risk Saf Med. 2016; 28(3):143–161. doi:10.3233/JRS-160728.CrossRefGoogle ScholarPubMed
Hovorka, M, Ewing, D, Middlemas, DS. Chronic SSRI treatment, but not norepinephrine reuptake inhibitor treatment, increases neurogenesis in juvenile rats. Int J Mol Sci. 2022; 23(13). doi:10.3390/ijms23136919.CrossRefGoogle Scholar
Doshi, P. No correction, no retraction, no apology, no comment: Paroxetine trial reanalysis raises questions about institutional responsibility. BMJ. 2015; 351:h4629. doi:10.1136/bmj.h4629.Google ScholarPubMed
Re-analysis of controversial Paxil study shows drug “ineffective and unsafe” for teens. Accessed March 26, 2023. https://retractionwatch.com/2015/09/16/re-analysis-of-controversial-paxil-study-shows-drug-ineffective-and-unsafe-for-teens/.Google Scholar
US Department of Justice, Office of Public Affairs. GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data. Accessed July 27, 2023. www.justice.gov/opa/pr/glaxosmithkline-plead-guilty-and-pay-3-billion-resolve-fraud-allegations-and-failure-report.Google Scholar
American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 3rd ed. 2010.Google Scholar
Cosgrove, L, Shaughnessy, AF, Wheeler, EE, Austad, KE, Kirsch, I, Bursztajn, HJ. The American Psychiatric Association’s guideline for major depressive disorder: A commentary. Psychother Psychosom. 2012; 81(3):186–188. doi:10.1159/000335523.CrossRefGoogle ScholarPubMed
Cosgrove, L, Bursztajn, HJ, Erlich, DR, Wheeler, EE, Shaughnessy, AF. Conflicts of interest and the quality of recommendations in clinical guidelines. J Eval Clin Pract. 2013; 19(4):674–681. doi:10.1111/jep.12016.CrossRefGoogle ScholarPubMed
Ioannidis, JP. Effectiveness of antidepressants: An evidence myth constructed from a thousand randomized trials? Philos Ethics Humanit Med. 2008; 3:14. doi:10.1186/1747-5341-3-14.CrossRefGoogle ScholarPubMed
Kirsch, I. The Emperor’s New Drugs: Exploding the Antidepressant Myth. Basic Books; 2010:xiv, p. 226.Google Scholar
Hollon, SD. Is cognitive therapy enduring or antidepressant medications iatrogenic? Depression as an evolved adaptation. Am Psychol. 2020; 75(9):1207–1218. doi:10.1037/amp0000728.CrossRefGoogle ScholarPubMed
Jakobsen, JC, Gluud, C, Kirsch, I. Should antidepressants be used for major depressive disorder? BMJ Evid Based Med. 2020; 25(4):130. doi:10.1136/bmjebm-2019-111238.CrossRefGoogle ScholarPubMed
World Health Organization. World mental health report: Transforming mental health for all (executive summary). 2022.Google Scholar
Rivero-Santana, A, Perestelo-Perez, L, Alvarez-Perez, Y, et al. Stepped care for the treatment of depression: A systematic review and meta-analysis. J Affect Disord. 2021; 294:391–409. doi:10.1016/j.jad.2021.07.008.CrossRefGoogle ScholarPubMed
Correll, CU, Solmi, M, Cortese, S, et al. The future of psychopharmacology: A critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents. World Psychiatry. 2023; 22(1):48–74. doi:10.1002/wps.21056.CrossRefGoogle ScholarPubMed
Carrillo, P, Petit, AC, Gaillard, R, Vinckier, F. The next psychoactive drugs: From imipramine to ketamine. Bull Acad Natl Med. 2020; 204(9):e169–e177. doi:10.1016/j.banm.2020.09.039.Google Scholar
Holper, L. Conditional power of antidepressant network meta-analysis. BMC Psychiatry. 2021; 21(1):129. doi:10.1186/s12888-021-03094-5.CrossRefGoogle ScholarPubMed
Kazdin, AE. Evidence-based treatment and practice: New opportunities to bridge clinical research and practice, enhance the knowledge base, and improve patient care. Am Psychol. 2008; 63(3):146–159. doi:10.1037/0003-066X.63.3.146.CrossRefGoogle ScholarPubMed
Cuijpers, P, Miguel, C, Harrer, M, et al. Cognitive behavior therapy vs. control conditions, other psychotherapies, pharmacotherapies and combined treatment for depression: A comprehensive meta-analysis including 409 trials with 52,702 patients. World Psychiatry. 2023; 22(1):105–115. doi:10.1002/wps.21069.CrossRefGoogle Scholar
Ventres, W, Boelen, C, Haq, C. Time for action: Key considerations for implementing social accountability in the education of health professionals. Adv Health Sci Educ Theory Pract. 2018; 23(4):853–862. doi:10.1007/s10459-017-9792-z.CrossRefGoogle ScholarPubMed
Frazzetto, G. The drugs don’t work for everyone. Doubts about the efficacy of antidepressants renew debates over the medicalization of common distress. EMBO Rep. 2008; 9(7):605–608. doi:10.1038/embor.2008.116.CrossRefGoogle ScholarPubMed
References
Alberts, B, Kirschner, MW, Tilghman, S, Varmus, H. Rescuing US biomedical research from its systemic flaws. Proc Natl Acad Sci USA. 2014; 111(16):5773–5777. doi:10.1073/pnas.1404402111.CrossRefGoogle ScholarPubMed
Gallo, SA, Schmaling, KB. Peer review: Risk and risk tolerance. PLoS One. 2022; 17(8):e0273813. doi:10.1371/journal.pone.0273813.CrossRefGoogle ScholarPubMed
Eblen, MK, Wagner, RM, RoyChowdhury, D, Patel, KC, Pearson, K. How criterion scores predict the overall impact score and funding outcomes for national institutes of health peer-reviewed applications. PLoS One. 2016; 11(6):e0155060. doi:10.1371/journal.pone.0155060.CrossRefGoogle ScholarPubMed
Schmaling, KB, Gallo, SA. Gender differences in peer reviewed grant applications, awards, and amounts: A systematic review and meta-analysis. Res Integr Peer Rev. 2023; 8(1):2. doi:10.1186/s41073-023-00127-3.CrossRefGoogle Scholar
Nakamura, RK, Mann, LS, Lindner, MD, et al. An experimental test of the effects of redacting grant applicant identifiers on peer review outcomes. Elife. 2021; 10. doi:10.7554/eLife.71368.CrossRefGoogle ScholarPubMed
Mintzes, B, Barer, ML, Kravitz, RL, et al. How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. CMAJ. 2003; 169(5):405–412.Google ScholarPubMed
Starc, A. Manufacturer spending on direct-to-consumer advertising for pharmaceutical products. JAMA. 2023; 329(5):371–373.CrossRefGoogle ScholarPubMed
DiStefano, MJ, Markell, JM, Doherty, CC, Alexander, GC, Anderson, GF. Association between drug characteristics and manufacturer spending on direct-to-consumer advertising. JAMA. 2023; 329(5):386–392.CrossRefGoogle ScholarPubMed
Wing, RR. The challenge of defining the optimal lifestyle weight loss intervention for real-world settings. JAMA. 2022; 328(22):2213–2214.CrossRefGoogle ScholarPubMed
Alalwan, AA, Friedman, J, Park, H, Segal, R, Brumback, BA, Hartzema, AG. US national trends in bariatric surgery: A decade of study. Surgery. 2021; 170(1):13–17.CrossRefGoogle ScholarPubMed
Woloshin, S, Jørgensen, KJ, Hwang, S, Welch, HG. The new USPSTF mammography recommendations – A dissenting view. N Engl J Med. 2023; 389(12):1061–1064.CrossRefGoogle ScholarPubMed
Lincoff, AM, Brown-Frandsen, K, Colhoun, HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023; 389(24):2221–2232. doi:10.1056/NEJMoa2307563.CrossRefGoogle ScholarPubMed
Mandrola, J. Positive results from SELECT begins a new era in cardiology. Medscape. 2023.Google Scholar
Koslowski, B. Scientific reasoning: Explanation, confirmation bias, and scientific practice. Handbook of the Psychology of Science. 2012:151–192.Google Scholar
Lord, CG, Ross, L, Lepper, MR. Biased assimilation and attitude polarization: The effects of prior theories on subsequently considered evidence. J Pers Soc Psychol. 1979; 37(11):2098.CrossRefGoogle Scholar
Nickerson, RS. Confirmation bias: A ubiquitous phenomenon in many guises. Rev General Psychol. 1998; 2(2):175–220.CrossRefGoogle Scholar
Kahneman, D, Lovallo, D, Sibony, O. Before you make that big decision. Harv Bus Rev. 2011; 89(6):50–60.Google ScholarPubMed
Makaram, NS, Lamb, SE, Simpson, AHR. Are we doing the right surgical trials?: The difficult nature of “true”equipoise. Bone Joint Res. 2023; 12(6):372.CrossRefGoogle Scholar
Miller, PB, Weijer, C. Rehabilitating equipoise. Kennedy Inst Ethics J. 2003; 13(2):93–118.CrossRefGoogle ScholarPubMed
Freedman, B. Equipoise and the ethics of clinical research. In Tomossy, G. F. and Weisstub, D. N., eds. Human Experimentation and Research. Routledge; 2017:427–431.CrossRefGoogle Scholar
Miller, FG, Joffe, S. Equipoise and the dilemma of randomized clinical trials. N Engl J Med. 2011; 364(5):476–480.CrossRefGoogle ScholarPubMed
Sneader, W. The discovery of aspirin: A reappraisal. BMJ. 2000; 321(7276):1591–1594. doi:10.1136/bmj.321.7276.1591.CrossRefGoogle Scholar
US Centers for Medicare and Medicaid Services. Open Payments Data. https://openpaymentsdata.cms.gov/.Google Scholar
Guan, ML, Pillinger, MH, Abeles, AM. Accuracy of financial disclosures in US-based rheumatology journals. Arthritis Care Res. 2024; 76(2):304–309. doi:10.1002/acr.25211.CrossRefGoogle ScholarPubMed
Abramson, JD. Sickening: How Big Pharma Broke American Health Care and How We Can Repair It. Mariner Books; 2022.Google Scholar
Jefferson, T, Jones, MA, Doshi, P, et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database Syst Rev. 2014; 2014(4):CD008965. doi:10.1002/14651858.CD008965.pub4.Google ScholarPubMed
Doshi, P, Jefferson, T. Tamiflu reviewers respond to critics. Nature. 2014; 509(7500):288.CrossRefGoogle ScholarPubMed
Jack, A. Tamiflu: “a nice little earner.” BMJ. 2014; 348:g2524. doi:10.1136/bmj.g2524.CrossRefGoogle ScholarPubMed
Ngo-Metzger, Q, Moyer, V, Grossman, D, et al. Conflicts of interest in clinical guidelines: Update of U.S. preventive services task force policies and procedures. Am J Prev Med. 2018; 54(1S1):S70–S80. doi:10.1016/j.amepre.2017.06.034.CrossRefGoogle ScholarPubMed
Carnes, M, Geller, S, Fine, E, Sheridan, J, Handelsman, J. NIH Director’s pioneer awards: Could the selection process be biased against women? J Womens Health (Larchmt). 2005; 14(8):684–691. doi:10.1089/jwh.2005.14.684.CrossRefGoogle ScholarPubMed
Pinn, VW. Sex and gender factors in medical studies: Implications for health and clinical practice. JAMA. 2003; 289(4):397–400. doi:10.1001/jama.289.4.397.CrossRefGoogle ScholarPubMed
Burchard, EG, Oh, SS, Foreman, MG, Celedón, JC. Moving toward true inclusion of racial/ethnic minorities in federally funded studies. A key step for achieving respiratory health equality in the United States. Am J Respir Crit Care Med. 2015; 191(5):514–521. doi:10.1164/rccm.201410-1944PP.CrossRefGoogle ScholarPubMed
Schmaling, KB, Kaplan, RM. Depression trial results: A cross-sectional study of ClinicalTrials.gov. J Psychiatr Res. 2023; 161:461–466.CrossRefGoogle ScholarPubMed
Schmaling, KB, Landon, HS, Nguyen, TB, Kaplan, RM. Transparency of results reporting for depression treatment studies in ClinicalTrials.gov: A cross-sectional study. BMJ Evid Based Med. 2022; 27(1):27–32.CrossRefGoogle ScholarPubMed
Kaplan, RM, Koong, AJ, Irvin, V. Review of evidence supporting 2022 US food and drug administration drug approvals. JAMA Netw Open. 2023; 6(8):e2327650.CrossRefGoogle ScholarPubMed
Kaplan, RM, Koong, AJ, Irvin, V. Food and Drug Administration novel drug decisions in 2017: Transparency and disclosure prior to and 5 years following approval. Health Aff Scholar. 2023; 1(2):qxad028.Google ScholarPubMed
Avorn, J, Kesselheim, AS. The 21st century cures act – Will it take us back in time? N Engl J Med. 2015; 372(26):2473–2475.CrossRefGoogle ScholarPubMed
Kaplan, RM. Sickening: Who is protecting pharma consumers? Perspect Biol Med. 2023; 66(2):327–343. doi:10.1353/pbm.2023.0018.CrossRefGoogle ScholarPubMed
Lovelace, B. Doctors say CDC should warn people the side effects from Covid vaccine shots won’t be “a walk in the park.” CNBC Changemakers. 2020.Google Scholar
Gee, J, Marquez, P, Su, J, et al. First month of COVID-19 vaccine safety monitoring – United States, December 14, 2020–January 13, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(8):283–288. doi:10.15585/mmwr.mm7008e3.CrossRefGoogle ScholarPubMed
See, I, Lale, A, Marquez, P, et al. Case series of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination – United States, December 2020 to August 2021. Ann Intern Med. 2022; 175(4):513–522. doi:10.7326/m21-4502.CrossRefGoogle ScholarPubMed
Zarin, DA, Fain, KM, Dobbins, HD, Tse, T, Williams, RJ. 10-year update on study results submitted to ClinicalTrials.gov. N Engl J Med. 2019; 381(20):1966–1974.CrossRefGoogle Scholar
Stephenson, J. In a First, FDA Warns Company to Remedy Failure to Post Clinical Trial Results. American Medical Association; 2021:e211306–e211306.CrossRefGoogle Scholar